Skip to main content
233 results

The BTS/NICE/SIGN asthma guidelines now recommend moving away from blue (reliever) and brown (preventer) inhalers. Many people with asthma still rely on their blue inhaler despite the fact they:

Anti-inflammatory reliever (AIR) is a single inhaler treatment for asthma which can be used by people with asthma and who experience asthma symptoms twice a week or less. It removes the need to have separate preventer (brown) and reliever (blue) inhalers. 

This document is a distillation of the new guidance to provide distinct advice on the changes on the diagnosis and management to asthma. It is not intended to be a comprehensive guide of the new guideline, neither does it cover all non-pharmacological treatments or on-going monitoring.

Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers. 

Inhalation is the main route for administration of drugs for conditions such as asthma or chronic obstructive pulmonary disease. The advantage of administering drugs by inhaler is that drugs are delivered directly to the site of action within the airways.

Knowing how to use Very Brief Advice to instigate a quit attempt and supporting smokers who are ready to quit is the business of every healthcare professional.Treating tobacco dependency systematically and effectively will have a significant impact on the triple aim:

In this article the authors review current evidence and guidance for the treatment of Chronic obstructive pulmonary disease (COPD) in order to bring up to date the Primary Care Respiratory Society (PCRS) consensus approach and algorithm first published in 2017 known as ‘Keeping it Simple’.

Since the publication of the Darzi Report1 and the new NHS 10-year Health Plan: Fit for the Future, there has been an increased focus on the delivery of Neighbourhood Health to reinforce integrated care and facilitate joined-up working between primary, secondary, community and social care.

My name is Russell Winwood; I’m 59 years old and have been living with severe COPD for the past 14 years. Nowadays I live very well with my COPD, but it hasn’t always been like this.

Point-of-care testing of C-reactive protein (CRP) for the acute assessment of worsening symptoms in people known to have COPD can safely reduce the use of antibiotics and could help improve the diagnostic approach towards someone presenting in such a crisis.

In this article the authors review current evidence and guidance for the treatment of Chronic obstructive pulmonary disease (COPD) to bring up to date the Primary Care Respiratory Society (PCRS) consensus approach and algorithm first published in 2017 and then again in 2023 known as ‘Keeping it S

Winter brings predictable surges in respiratory illness and pressure across urgent and emergency care. This paper sets out a practical, primary care-led framework to reduce avoidable demand by acting earlier on respiratory risk. We describe seven interventions:

This summary infographic provides an overview of the new MART therapy which has been licensed for children of 6 - 11 years old.

In this PCRS Health Inequalities podcast Leslie Borrill and Rebecca Jacobs discuss suicide and suicide prevention in long-term respiratory conditions. They cover: